FindTrial
Sign In

Trail against hyperlipidemia patients with high risks to investigate the effect on small dense LDL-C & IDL by using middle dose Rosuvastatin in Saitama

Trail against hyperlipidemia patients with high risks to investigate the effect on small dense LDL-C & IDL by using middle dose Rosuvastatin in Saitama - PIONEER Saitama

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000006539
Enrollment
200
Registered
2011-11-07
Start date
2011-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Interventions

Rosuvastatin 5mg-20mg for 6 month

Sponsors

Ikuo Inoue
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)-3) 3 examine group 1)T2DM with 120 mg/dl or more than 120 mg/dl LDL-C 2)Patients of JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2007 CategoryIII (Diabetes patients are excepted) with 120 mg/dl or more than 120 mg/dl LDL-C 3)Patients of JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2007 Secondary prevention with 100 mg/dl or more than 100 mg/dl LDL-C

Exclusion criteria

Exclusion criteria: A patient with the side-effects past in statin medication

Design outcomes

Primary

MeasureTime frame
Lipid profile (TC,TG,HDL-C, Friedewald LDL-C,small dense LDL,IDL),apo protein, apoE phenotype—

Secondary

MeasureTime frame
Cr, BUN, Urinal analysis, GOT, GPT, CK, (following in the case of DM), fasting blood glucose, HbA1c. The coronary computed tomographic angiography (CCTA) was repeated and compared before and after treatment.—

Countries

Japan

Contacts

Public ContactIkuo Inoue

Saitama Medical University Dept. of Endocrinology and Diabetology

i1901018@saitama-med.ac.jp049-276-1875

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026